Literature DB >> 23708659

RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B.

C F Wu1, S Liu2, Y-C Lee3, R Wang1, S Sun4, F Yin2, W G Bornmann1, L-Y Yu-Lee5, G E Gallick6, W Zhang2, S-H Lin7, J Kuang4.   

Abstract

Activation of the mitogen-activated protein kinase (MAPK) cascade in mammalian cell lines positively regulates the G2/M transition. The molecular mechanism underlying this biological phenomenon remains poorly understood. Ribosomal S6 kinase (RSK) is a key downstream element of the MAPK cascade. Our previous studies established roles of RSK2 in Cdc25C activation during progesterone-induced meiotic maturation of Xenopus oocytes. In this study we demonstrate that both recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylate all three isoforms of human Cdc25 at a conserved motif near the catalytic domain. In human HEK293 and PC-3mm2 cell lines, RSK preferentially phosphorylates Cdc25A and Cdc25B in mitotic cells. Phosphorylation of the RSK sites in these Cdc25 isoforms increases their M-phase-inducing activities. Inhibition of RSK-mediated phosphorylation of Cdc25 inhibits G2/M transition. Moreover, RSK is likely to be more active in mitotic cells than in interphase cells, as evidenced by the phosphorylation status of T359/S363 in RSK. Together, these findings indicate that RSK promotes G2/M transition in mammalian cells through activating phosphorylation of Cdc25A and Cdc25B.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708659      PMCID: PMC4026278          DOI: 10.1038/onc.2013.182

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  64 in total

Review 1.  The MEK/ERK cascade: from signaling specificity to diverse functions.

Authors:  Yoav D Shaul; Rony Seger
Journal:  Biochim Biophys Acta       Date:  2006-10-19

2.  RSK and MSK in MAP kinase signalling.

Authors:  Camilla Hauge; Morten Frödin
Journal:  J Cell Sci       Date:  2006-08-01       Impact factor: 5.285

Review 3.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

4.  The ERK-RSK1 activation by growth factors at G2 phase delays cell cycle progression and reduces mitotic aberrations.

Authors:  Hyun-Ja Nam; Sujeong Kim; Min-Woo Lee; Bok-Soon Lee; Toshihiro Hara; Hideyuki Saya; Hyeseong Cho; Jae-Ho Lee
Journal:  Cell Signal       Date:  2008-03-21       Impact factor: 4.315

Review 5.  The RSK family of kinases: emerging roles in cellular signalling.

Authors:  Rana Anjum; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2008-10       Impact factor: 94.444

6.  Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.

Authors:  Maria Giulia Cangi; Sara Piccinin; Lorenza Pecciarini; Anna Talarico; Elena Dal Cin; Stefano Grassi; Alessandra Grizzo; Roberta Maestro; Claudio Doglioni
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 7.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

Review 8.  The RSK factors of activating the Ras/MAPK signaling cascade.

Authors:  Audrey Carriere; Hind Ray; John Blenis; Philippe P Roux
Journal:  Front Biosci       Date:  2008-05-01

Review 9.  The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability.

Authors:  Yue Chen; Randy Y C Poon
Journal:  Front Biosci       Date:  2008-05-01

10.  Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents.

Authors:  Bernadette Aressy; Béatrix Bugler; Annie Valette; Denis Biard; Bernard Ducommun
Journal:  Cell Cycle       Date:  2008-05-14       Impact factor: 4.534

View more
  13 in total

1.  Phosphorylation of CDC25A on SER283 in late S/G2 by CDK/cyclin complexes accelerates mitotic entry.

Authors:  Laurent Mazzolini; Anaïs Broban; Carine Froment; Odile Burlet-Schiltz; Arnaud Besson; Stéphane Manenti; Christine Dozier
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

2.  MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.

Authors:  Guo-qing Song; Yi Zhao
Journal:  Tumour Biol       Date:  2015-02-14

3.  RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival.

Authors:  Guoyu Yu; Yu-Chen Lee; Chien-Jui Cheng; Chuan-Fen Wu; Jian H Song; Gary E Gallick; Li-Yuan Yu-Lee; Jian Kuang; Sue-Hwa Lin
Journal:  Mol Cancer Res       Date:  2014-09-04       Impact factor: 5.852

4.  Phosphorylation-Dependent Activation of the ESCRT Function of ALIX in Cytokinetic Abscission and Retroviral Budding.

Authors:  Sheng Sun; Le Sun; Xi Zhou; Chuanfen Wu; Ruoning Wang; Sue-Hwa Lin; Jian Kuang
Journal:  Dev Cell       Date:  2016-02-08       Impact factor: 12.270

5.  Multi-Omics Analysis and Machine Learning Prediction Model for Pregnancy Outcomes After Intracytoplasmic Sperm Injection-in vitro Fertilization.

Authors:  Fangying Chen; Yixin Chen; Qinyun Mai
Journal:  Front Public Health       Date:  2022-06-30

6.  High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Tumour Biol       Date:  2014-03

Review 7.  The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.

Authors:  Ryan Cronin; Greg N Brooke; Filippo Prischi
Journal:  Oncogene       Date:  2021-05-10       Impact factor: 9.867

8.  Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.

Authors:  Corinna Kosnopfel; Tobias Sinnberg; Birgit Sauer; Heike Niessner; Anja Schmitt; Elena Makino; Andrea Forschner; Stephan Hailfinger; Claus Garbe; Birgit Schittek
Journal:  Oncotarget       Date:  2017-05-30

9.  Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.

Authors:  Suman Chatterjee; Eric H-B Huang; Ian Christie; Timothy F Burns
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

10.  Establishment of Immortalized BMP2/4 Double Knock-Out Osteoblastic Cells Is Essential for Study of Osteoblast Growth, Differentiation, and Osteogenesis.

Authors:  Li-An Wu; Feng Wang; Kevin J Donly; Andrew Baker; Chunyan Wan; Daoshu Luo; Mary MacDougall; Shuo Chen
Journal:  J Cell Physiol       Date:  2015-12-28       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.